Status:
COMPLETED
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease
Lead Sponsor:
Ruttonjee Hospital
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Clopidogrel can reduce risk of cardiovascular disease by inhibiting platelet aggregation. It is metabolized to an active drug by a liver enzyme. Its efficacy may be measured by blood sampling for plat...
Detailed Description
Clopidogrel is a pro-drug, which requires hepatic transformation by the cytochrome P450 isoform 3A4 to generate the active metabolite. It inhibits adenosine-5-diphosphate (ADP)-induced platelet aggreg...
Eligibility Criteria
Inclusion
- ischemic heart disease patient, and
- given loading or maintenance dose of clopidogrel and in need of it for 1 or more month
- and in need of additional drug for optimal BP control (aim blood pressure \<130/90) or angina control.
Exclusion
- existing use of amlodipine
- thrombocytopenia
- end stage renal failure
- allergy to clopidogrel/ amlodipine
- pregnancy/ lactation
- strong inhibitor or inducer of cytochrome P450 3A4 enzyme within 7 days before start of the study.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT01203696
Start Date
July 1 2010
End Date
April 1 2011
Last Update
June 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruttonjee Hospital
Hong Kong SAR, China